1 not yet recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Fallopian Tube Cancers: new trials by email Literature Review of Fallopian Tube Cancers trials Research Report on Fallopian Tube Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-03-16 |
| JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer JSKN003, Doxorubicin, Paclitaxel - Ovarian Cancer, Primary Peritoneal | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 430 | 2025-01-15 | 2024-12-31 |
Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2)
Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
Bevacizumab (1) · Doxorubicin (1) · Paclitaxel (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · Topotecan (1)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1) · N.N. Alexandrov National Cancer Centre (1)
Belarus (1)